ID   G583
AC   CVCL_B4P8
SY   G583NS
DR   EGA; EGAS00001003493
DR   EGA; EGAS00001003700
DR   GEO; GSM3439935
DR   GEO; GSM3439936
DR   GEO; GSM3439937
DR   GEO; GSM3439944
DR   GEO; GSM3439945
DR   GEO; GSM3439946
DR   Wikidata; Q110432808
RX   PubMed=31249064;
RX   PubMed=30995489;
CC   Group: Cancer stem cell line.
CC   Omics: CTCF ChIP-seq epigenome analysis.
CC   Omics: H3K27ac ChIP-seq epigenome analysis.
CC   Omics: Hi-C chromosome conformation analysis.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Brain; UBERON=UBERON_0000955.
DI   NCIt; C3058; Glioblastoma
DI   ORDO; Orphanet_360; Glioblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   51Y
CA   Cancer cell line
DT   Created: 16-12-21; Last updated: 05-10-23; Version: 5
//
RX   PubMed=31249064; DOI=10.1101/gr.246520.118;
RA   Johnston M.J., Nikolic A., Ninkovic N., Guilhamon P., Cavalli F.M.G.,
RA   Seaman S., Zemp F.J., Lee J., Abdelkareem A., Ellestad K., Murison A.,
RA   Kushida M.M., Coutinho F.J., Ma Y., Mungall A.J., Moore R.,
RA   Marra M.A., Taylor M.D., Dirks P.B., Pugh T.J., Morrissy A.S.,
RA   St Croix B., Mahoney D.J., Lupien M., Gallo M.;
RT   "High-resolution structural genomics reveals new therapeutic
RT   vulnerabilities in glioblastoma.";
RL   Genome Res. 29:1211-1222(2019).
//
RX   PubMed=30995489; DOI=10.1016/j.celrep.2019.03.047;
RA   MacLeod G., Bozek D.A., Rajakulendran N., Monteiro V., Ahmadi M.,
RA   Steinhart Z., Kushida M.M., Yu H., Coutinho F.J., Cavalli F.M.G.,
RA   Restall I.J., Hao X.-G., Hart T., Luchman H.A., Weiss S., Dirks P.B.,
RA   Angers S.;
RT   "Genome-wide CRISPR-Cas9 screens expose genetic vulnerabilities and
RT   mechanisms of temozolomide sensitivity in glioblastoma stem cells.";
RL   Cell Rep. 27:971-986.e9(2019).
//